Joe Daley, GSW WORLDWIDE
At the end of the day you have tribes, some frequently not on the same "brand" page.
Joe Daley
PRESIDENT | GSW WORLDWIDE/US OPERATIONS
Waste is actually inherent in the very question. We manage investment decisions in silos. Our teams (client/agency team) are traditionally aligned functionally, or by communication channels, or by business segments, or by whatever the niche of the day happens to be. Many clients have functional experts, whether it's PR, medical education, e-marketing, etc. Some clients have strategic marketing separated from tactical marketing (the latter taking the form of marcom-like functions). At the end of the day you have tribes, some frequently not on the same "brand" page. Take the most talented, best marketers, but if you put them in different rooms and ask them as a team to paint a picture of a single apple, the results will not cohere.
Joe Daley
On the top line, waste is created by not leveraging a single brand experience, through fewer tactics, synergistically connected, and strategically driven through channels likely to reach a target audience. ?On the bottom line, it's needless investment in disconnected tactical ideas, and redundancy of functions/people, among other redundancies.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
